Portal de investigação
Mineralocorticoid receptor antagonist indication and underuse in high-risk post-myocardial infarction patients
Autores da FMUP
Participantes de fora da FMUP
- Rossello, X
- Zannad, F
Unidades de investigação
Abstract
[No abstract available]
Dados da publicação
- ISSN/ISSNe:
- 1388-9842, 1879-0844
- Tipo:
- Editorial Material
- Páginas:
- 140-141
- DOI:
- 10.1002/ejhf.3098
- Link para outro recurso:
- www.scopus.com
European Journal of Heart Failure Wiley-Blackwell
Documentos
- Não há documentos
Filiações
Keywords
- Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Spironolactone; ramipril; sacubitril plus valsartan; mineralocorticoid antagonist; spironolactone; all cause mortality; cardiovascular mortality; confidence interval; drug efficacy; drug indication; drug safety; Editorial; hazard ratio; heart failure; heart infarction; high risk patient; human; hyperkalemia; hypotension; treatment outcome; undertreatment; heart failure
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023
Citar a publicação
Ferreira JP,Rossello X,Zannad F. Mineralocorticoid receptor antagonist indication and underuse in high-risk post-myocardial infarction patients. Eur. J. Heart Fail. 2023. 26(1):p. 140-141. IF:18,200. (1).
